|
|
|
|
|
Sertaconazole
drug data and news
Sertaconazole drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Sertaconazole | ||
| Brand Names/Synonyms | Ertaczo; FI-7045; SZ; Sertaconazol [Spanish]; Sertaconazole; Sertaconazole Nitrate; Sertaconazole [Inn]; Sertaconazolum [Latin] | ||
| Indication | For the topical treatment of interdigital tinea pedis in immunocompetent patients 12 years of age and older, caused by Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Sertaconazole is an imidazole/triazole type antifungal agent. Sertaconazole is a highly selective inhibitor of fungal cytochrome P-450 sterol C-14 α-demethylation via the inhibition of the enzyme cytochrome P450 14α-demethylase. This enzyme converts lanosterol to ergosterol, and is required in fungal cell wall synthesis. The subsequent loss of normal sterols correlates with the accumulation of 14 α-methyl sterols in fungi and may be partly responsible for the fungistatic activity of fluconazole. Mammalian cell demethylation is much less sensitive to fluconazole inhibition. Sertaconazole exhibits in vitro activity against Cryptococcus neoformans and Candida spp. Fungistatic activity has also been demonstrated in normal and immunocompromised animal models for systemic and intracranial fungal infections due to Cryptococcus neoformans and for systemic infections due to Candida albicans. | ||
| Mechanism Of Action | Sertaconazole interacts with 14-α demethylase, a cytochrome P-450 enzyme necessary to convert lanosterol to ergosterol. As ergosterol is an essential component of the fungal cell membrane, inhibition of its synthesis results in increased cellular permeability causing leakage of cellular contents. Sertaconazole may also inhibit endogenous respiration, interact with membrane phospholipids, inhibit the transformation of yeasts to mycelial forms, inhibit purine uptake, and impair triglyceride and/or phospholipid biosynthesis. | ||
| Sertaconazole News (When available) |
| ||
| Dosage Forms | Cream (2% contains 17.5 mg of sertaconazole) | ||
| Drug_Category | Antifungal Agents; ATC:D01AC14 | ||
| Absorption | Not Available | ||
| Interactions |
Interactions for Sertaconazole: Drug/Laboratory Test Interactions: Potential interactions between ERTACZOTM Cream, 2%, and other drugs or laboratory tests have not been systematically evaluated. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Yeast and other fungi | ||
| Chemical IUPAC Name | 1-[2-[(7-chlorobenzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)-ethyl]imidazole | ||
| Chemical Formula | C20H15Cl3N2OS | ||
| Molecular Weight | 437.77 g/mol | ||
| Smiles String | C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl | ||
| Melting Point | Not Available | ||
| Water Solubility | Practically insoluble | ||
| State | Solid (white or almost white powder) | ||
| LogP/Hphobicity | 5.952 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | Not Available | ||
| Protein Binding [%] | >99%-plasma | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Sertaconazole.html http://www.rxlist.com/cgi/generic3/ertaczo.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00305 | ||
| CAS Registry Number | 99592-32-2 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:207904 | ||
| PharmGKB ID | PA10184 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |